Pharmacokinetics of H3B-6545 in patients with locally advanced or metastatic estrogen receptor-positive HER2 negative breast cancer (ER+ and HER2-BC)

被引：0
|
作者：
Majid, Oneeb [1 ]
Xiao, Jianjun Alan [2 ]
Sahmoud, Tarek [2 ]
Yasuda, Sanae [3 ]
Cantagallo, Lisa [2 ]
Hamilton, Erika P. [4 ]
Pluard, Timothy [5 ]
Juric, Dejan [6 ]
Gualberto, Antonio [2 ]
Husseiin, Ziad [1 ]
机构：
[1] Eisai, Hatfield, Herts, England
[2] H3 Biomed, Cambridge, MA USA
[3] Eisai Inc, Woodcliff Lake, NJ USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] St Lukes Canc Inst, Kansas City, MO USA
[6] Massachusetts Gen Hosp, Boston, MA 02114 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS12-15
引用
收藏
页数：1
相关论文
共 50 条
  • [1] H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
    Hamilton, Erika P.
    Pluard, Timothy J.
    Wang, Judy S.
    Morikawa, Aki
    Johnston, Stephen R. D.
    Dees, Elizabeth Claire
    Vaklavas, Christos
    Armstrong, Anne C.
    Munster, Pamela N.
    Unni, Nisha
    Wright, Gail Lynn Shaw
    Kayali, Fadi
    Song, Tingting
    Rong, Yuanxin
    Yamaguchi, Kohei
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] H3B-6545+palbociclib in patients (pts) with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (-) breast cancer (BC)
    Johnston, Stephen R. D.
    Pluard, Timothy J.
    Wang, Judy S.
    Hamilton, Erika P.
    Song, Tingting
    Rong, Yuanxin
    Yamaguchi, Kohei
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2 (HER2)-negative breast cancer, phase 1b study
    Johnston, Stephen
    Pluard, Timothy J.
    Wang, Judy S.
    Hamilton, Erika P.
    Juric, Dejan
    Scholz, Catherine R.
    Hnitecki, Elizabeth
    Dar, Sara
    Gao, Lei
    Cantagallo, Lisa
    Korpal, Manav
    Xiao, Jianjun Alan
    Yu, Lihua
    Sahmoud, Tarek
    Gualberto, Antonio
    CANCER RESEARCH, 2022, 82 (04)
  • [4] Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor-positive (ER plus ), human epidermal growth factor receptor 2 (HER2)-negative breast cancer.
    Johnston, Stephen R. D.
    Pluard, Timothy J.
    Wang, Judy S.
    Hamilton, Erika P.
    Juric, Dejan
    Scholz, Catherine Rose
    Hnitecki, Elizabeth
    Gao, Lei
    Cantagallo, Lisa
    Korpal, Manav
    Destenaves, Benoit
    Xiao, Jianjun Alan
    Zhang, Zhaojie
    Pipas, J. Marc Marc
    Yu, Lihua
    Sahmoud, Tarek
    Gualberto, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [5] Phase lb study of LEE011 and BYL719 in combination with letrozole in estrogen receptor-positive, HER2-negative breast cancer (ER+, HER2-BC).
    Munster, Pamela N.
    Hamilton, Erika Paige
    Franklin, Catherine
    Bhansali, Suraj
    Wan, Kitty
    Hewes, Becker
    Juric, Dejan
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Analysis of estrogen receptor positive (ER+), progesterone receptor negative (PR-) phenotype and HER2 status in breast cancer (BC) patients
    Mitrovic, Slobodanka
    Stankovic, Vesna
    Azanjac, Goran
    Ninkovic, Srdan
    VIRCHOWS ARCHIV, 2007, 451 (02) : 299 - 299
  • [7] Phase I study of H3B-6545 in patients (pts) with estrogen receptor-positive (ER plus ) breast cancer
    Ono, M.
    Kogawa, T.
    Kitano, S.
    Shimoi, T.
    Yamamoto, K.
    Kobayashi, S.
    Ichikawa, Y.
    Yamaguchi, K.
    Otake, Y.
    Hojo, S.
    Yonemori, K.
    ANNALS OF ONCOLOGY, 2023, 34 : S1487 - S1487
  • [8] Mechanisms of resistance to estrogen receptor modulators in ER+/HER2− advanced breast cancer
    Jin Zhang
    Qianying Wang
    Qing Wang
    Jiangran Cao
    Jiafu Sun
    Zhengmao Zhu
    Cellular and Molecular Life Sciences, 2020, 77 : 559 - 572
  • [9] evERA Breast Cancer (BC): Phase III study of giredestrant plus everolimus vs exemestane plus everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2-LA/mBC)
    Mayer, Erica L.
    Tolaney, Sara M.
    Brufsky, Adam
    Gradishar, William John
    Jhaveri, Komal L.
    Martin, Miguel
    Moscetti, Luca
    Schneeweiss, Andreas
    Vidal, Gregory A.
    Cortazar, Patricia
    Feldman, Merilin
    Day, Bann-mo
    Rugo, Hope S.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER plus ), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer - A phase II study
    Hamilton, Erika P.
    Wang, Judy S.
    Pluard, Timothy
    Morikawa, Aki
    Dees, E. Claire
    Jones, Robert H.
    Haley, Barbara
    Armstrong, Anne
    Cohen, Adam L.
    Munster, Pamela
    Wright, Gail S.
    Kayali, Fadi
    Cantagallo, Lisa
    Korpal, Manav
    Long, Jenny
    Xiao, Jianjun
    Destenaves, Benoit
    Gao, Lei
    Sahmoud, Tarek
    Gualberto, Antonio
    Juric, Dejan
    CANCER RESEARCH, 2022, 82 (04)
12345